Paclitaxel trevatide

DB06171InvestigationalProtein Based Therapies

Three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2, conjugate named ANG1005.

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in brain cancer.Curator reviewed
Also known as
[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr
Code names
ANG-1005

Resolves to

Compound
UNII8P77G99D3PCAS1075214-55-9
Targets
Q07954LRP1

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
94Drug interactionsStructured to mechanism, not free text
Sign in
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Paclitaxel trevatide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In